Market Cap 8.73B
Revenue (ttm) 12.82B
Net Income (ttm) 936.34M
EPS (ttm) N/A
PE Ratio 12.61
Forward PE 11.62
Profit Margin 7.31%
Debt to Equity Ratio -33.86
Volume 684,479
Avg Vol 836,566
Day's Range N/A - N/A
Shares Out 70.60M
Stochastic %K 74%
Beta 1.13
Analysts Hold
Price Target $144.00

Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative se...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 720-631-2100
Address:
2000 16th Street, Denver, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:32 AM
$DVA: The current market context shows a recent close at $121.55, with an RSI of 33.91 indicating that the stock is in oversold territory. The 30-day moving average (MA30) is at $124.91, while the 50-day moving average (MA50) is higher at $127.7, suggesting a bearish trend as the price is below both MAs. The 60-day high of $141.77 and low of $115.39 indicate a range that the stock has recently traded within, with the current price closer to the low end. Directional bias leans bearish due to the RSI and the price being below both MAs. Suggested entry is at $121.00, with a stop-loss at $118.00 to limit downside risk. Target 1 is set at $125.00 (near MA30), and Target 2 at $128.00 (near MA50). Monitor for any reversal signals as the stock approaches these targets. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:06 AM
$DVA: The current market context shows a last close at $123.05, with an RSI of 37.06 indicating the stock is in the oversold territory, suggesting potential for a reversal. The price is below both the 30-day moving average (MA30) of $125.23 and the 50-day moving average (MA50) of $128.03, indicating a bearish trend. The 60-day high of $141.77 and low of $115.39 suggest a wide trading range, providing potential for volatility. Directional bias is bearish due to the price being below key moving averages, but the low RSI indicates a possible short-term reversal opportunity. Suggested entry: $123.50, with a stop loss at $120.00 to manage risk. Target 1: $128.00 (near MA50), Target 2: $130.00 (psychological level). Monitor the ATR of 3.65 for potential volatility adjustments. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:12 AM
$DVA is currently trading at $122.27, showing a bearish market context as indicated by an RSI of 35.85, suggesting oversold conditions but potential for further downside. The price is below both the 30-day moving average (MA30) of $125.84 and the 50-day moving average (MA50) of $128.52, reinforcing a bearish trend. The recent high of $141.77 and low of $115.39 over the last 60 days indicates a significant range, with potential support near the low. Suggested entry point is around $121.50, slightly below the current price to capture potential downside momentum. Set a stop loss at $119.00 to manage risk. Target 1 is $125.00, aligning with the MA30, and Target 2 is $128.00, near the MA50. This plan allows for a favorable risk-reward ratio while considering the current market dynamics. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:48 AM
$DVA is currently trading at $122.27, showing a bearish market context as indicated by an RSI of 35.85, suggesting oversold conditions but potential for further downside. The price is below both the 30-day moving average (MA30) of $125.84 and the 50-day moving average (MA50) of $128.52, reinforcing a bearish trend. The recent high of $141.77 and low of $115.39 over the last 60 days indicates a significant range, with potential support near the low. Suggested entry point is around $121.50, slightly below the current price to capture potential downside momentum. Set a stop loss at $119.00 to manage risk. Target 1 is $125.00, aligning with the MA30, and Target 2 is $128.00, near the MA50. This plan allows for a favorable risk-reward ratio while considering the current market dynamics. https://privateprofiteers.com
0 · Reply
Noname2022
Noname2022 Nov. 12 at 12:18 AM
$DVA When will Defencath go village wide?
0 · Reply
NUWE_to_the_moon
NUWE_to_the_moon Nov. 11 at 11:39 PM
$NUWE with the increase in government reimbursements for aquadex outpatients earlier this year, it's quite possible Davita $DVA acquires $NUWE sometime in the near future. Hopefully during tomorrow's call they can show increase in revenue with the improved reimbursements and send this bitch to the moon.
0 · Reply
Noname2022
Noname2022 Nov. 11 at 7:31 PM
$AKBA $DVA Day after Akebia’s launch, DaVita’s already hosting a CE on compliance the echo from the earnings call couldn’t be louder
1 · Reply
RyGuy_79
RyGuy_79 Nov. 9 at 4:34 AM
$CRMD $DVA Either StockTwits’ AI is hallucinating, or they are privy to inside information concerning Defencath as it pertains to Davita. No way this was actually trending at any point today.
1 · Reply
RyGuy_79
RyGuy_79 Nov. 9 at 4:09 AM
$DVA Why was this trending?
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 9 at 2:49 AM
gonna wait for H% to cool down before buying $DVA like usual
0 · Reply
Latest News on DVA
DaVita Inc. to Participate in Fireside Chat with Wolfe Research

Nov 14, 2025, 4:16 PM EST - 3 hours ago

DaVita Inc. to Participate in Fireside Chat with Wolfe Research


DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 7:46 PM EDT - 16 days ago

DaVita Inc. (DVA) Q3 2025 Earnings Call Transcript


DaVita Inc. 3rd Quarter 2025 Results

Oct 29, 2025, 4:05 PM EDT - 16 days ago

DaVita Inc. 3rd Quarter 2025 Results


DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call

Oct 13, 2025, 2:00 PM EDT - 4 weeks ago

DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call


DaVita: Aggressive Buybacks Despite Rising Cost Of Debt

Aug 20, 2025, 9:36 AM EDT - 3 months ago

DaVita: Aggressive Buybacks Despite Rising Cost Of Debt


DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:02 PM EDT - 3 months ago

DaVita Inc. (DVA) Q2 2025 Earnings Call Transcript


DaVita Inc. 2nd Quarter 2025 Results

Aug 5, 2025, 4:05 PM EDT - 3 months ago

DaVita Inc. 2nd Quarter 2025 Results


DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

Jul 17, 2025, 5:37 PM EDT - 4 months ago

DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call


DaVita: International Expansion And Buybacks Will Boost Returns

May 27, 2025, 11:30 AM EDT - 6 months ago

DaVita: International Expansion And Buybacks Will Boost Returns


DaVita Inc. Announces Offering of $750 Million Senior Notes

May 20, 2025, 8:51 AM EDT - 6 months ago

DaVita Inc. Announces Offering of $750 Million Senior Notes


DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript

May 12, 2025, 9:41 PM EDT - 6 months ago

DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript


DaVita First-Quarter 2025 Financial Results: Just the Numbers

May 12, 2025, 4:51 PM EDT - 6 months ago

DaVita First-Quarter 2025 Financial Results: Just the Numbers


DaVita Inc. 1st Quarter 2025 Results

May 12, 2025, 4:05 PM EDT - 6 months ago

DaVita Inc. 1st Quarter 2025 Results


DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

Apr 30, 2025, 11:00 AM EDT - 7 months ago

DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call


DaVita Says Ransomware Attack Affecting Some Operations

Apr 14, 2025, 7:35 AM EDT - 7 months ago

DaVita Says Ransomware Attack Affecting Some Operations


Dialysis firm DaVita hit by ransomware attack

Apr 14, 2025, 7:33 AM EDT - 7 months ago

Dialysis firm DaVita hit by ransomware attack


Berkshire Hathaway sells another 750,000 DaVita shares

Feb 19, 2025, 8:05 PM EST - 9 months ago

Berkshire Hathaway sells another 750,000 DaVita shares


DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 8:19 PM EST - 9 months ago

DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript


Berkshire sells some DaVita shares, cuts stake to 45%

Feb 13, 2025, 8:13 PM EST - 9 months ago

Berkshire sells some DaVita shares, cuts stake to 45%


DaVita forecasts 2025 profit below estimates, shares plummet

Feb 13, 2025, 6:07 PM EST - 9 months ago

DaVita forecasts 2025 profit below estimates, shares plummet


DaVita Inc. 4th Quarter 2024 Results

Feb 13, 2025, 4:05 PM EST - 9 months ago

DaVita Inc. 4th Quarter 2024 Results


DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

Jan 30, 2025, 11:55 AM EST - 10 months ago

DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call


DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 9:27 PM EDT - 1 year ago

DaVita Inc. (DVA) Q3 2024 Earnings Call Transcript


DaVita misses third-quarter profit estimates on higher costs

Oct 29, 2024, 4:23 PM EDT - 1 year ago

DaVita misses third-quarter profit estimates on higher costs


DaVita Inc. 3rd Quarter 2024 Results

Oct 29, 2024, 4:05 PM EDT - 1 year ago

DaVita Inc. 3rd Quarter 2024 Results


PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:32 AM
$DVA: The current market context shows a recent close at $121.55, with an RSI of 33.91 indicating that the stock is in oversold territory. The 30-day moving average (MA30) is at $124.91, while the 50-day moving average (MA50) is higher at $127.7, suggesting a bearish trend as the price is below both MAs. The 60-day high of $141.77 and low of $115.39 indicate a range that the stock has recently traded within, with the current price closer to the low end. Directional bias leans bearish due to the RSI and the price being below both MAs. Suggested entry is at $121.00, with a stop-loss at $118.00 to limit downside risk. Target 1 is set at $125.00 (near MA30), and Target 2 at $128.00 (near MA50). Monitor for any reversal signals as the stock approaches these targets. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:06 AM
$DVA: The current market context shows a last close at $123.05, with an RSI of 37.06 indicating the stock is in the oversold territory, suggesting potential for a reversal. The price is below both the 30-day moving average (MA30) of $125.23 and the 50-day moving average (MA50) of $128.03, indicating a bearish trend. The 60-day high of $141.77 and low of $115.39 suggest a wide trading range, providing potential for volatility. Directional bias is bearish due to the price being below key moving averages, but the low RSI indicates a possible short-term reversal opportunity. Suggested entry: $123.50, with a stop loss at $120.00 to manage risk. Target 1: $128.00 (near MA50), Target 2: $130.00 (psychological level). Monitor the ATR of 3.65 for potential volatility adjustments. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:12 AM
$DVA is currently trading at $122.27, showing a bearish market context as indicated by an RSI of 35.85, suggesting oversold conditions but potential for further downside. The price is below both the 30-day moving average (MA30) of $125.84 and the 50-day moving average (MA50) of $128.52, reinforcing a bearish trend. The recent high of $141.77 and low of $115.39 over the last 60 days indicates a significant range, with potential support near the low. Suggested entry point is around $121.50, slightly below the current price to capture potential downside momentum. Set a stop loss at $119.00 to manage risk. Target 1 is $125.00, aligning with the MA30, and Target 2 is $128.00, near the MA50. This plan allows for a favorable risk-reward ratio while considering the current market dynamics. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:48 AM
$DVA is currently trading at $122.27, showing a bearish market context as indicated by an RSI of 35.85, suggesting oversold conditions but potential for further downside. The price is below both the 30-day moving average (MA30) of $125.84 and the 50-day moving average (MA50) of $128.52, reinforcing a bearish trend. The recent high of $141.77 and low of $115.39 over the last 60 days indicates a significant range, with potential support near the low. Suggested entry point is around $121.50, slightly below the current price to capture potential downside momentum. Set a stop loss at $119.00 to manage risk. Target 1 is $125.00, aligning with the MA30, and Target 2 is $128.00, near the MA50. This plan allows for a favorable risk-reward ratio while considering the current market dynamics. https://privateprofiteers.com
0 · Reply
Noname2022
Noname2022 Nov. 12 at 12:18 AM
$DVA When will Defencath go village wide?
0 · Reply
NUWE_to_the_moon
NUWE_to_the_moon Nov. 11 at 11:39 PM
$NUWE with the increase in government reimbursements for aquadex outpatients earlier this year, it's quite possible Davita $DVA acquires $NUWE sometime in the near future. Hopefully during tomorrow's call they can show increase in revenue with the improved reimbursements and send this bitch to the moon.
0 · Reply
Noname2022
Noname2022 Nov. 11 at 7:31 PM
$AKBA $DVA Day after Akebia’s launch, DaVita’s already hosting a CE on compliance the echo from the earnings call couldn’t be louder
1 · Reply
RyGuy_79
RyGuy_79 Nov. 9 at 4:34 AM
$CRMD $DVA Either StockTwits’ AI is hallucinating, or they are privy to inside information concerning Defencath as it pertains to Davita. No way this was actually trending at any point today.
1 · Reply
RyGuy_79
RyGuy_79 Nov. 9 at 4:09 AM
$DVA Why was this trending?
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Nov. 9 at 2:49 AM
gonna wait for H% to cool down before buying $DVA like usual
0 · Reply
Noname2022
Noname2022 Nov. 8 at 9:06 PM
$CRMD $AKBA $FMS $DVA Remember: the post-TDAPA add-on policy itself was created through a CMS Final Rule change in 2024. That rule added three additional years of payment support after TDAPA ended. The same rule making pathway could just as easily be used again to extend the TDAPA period itself to three years. CMS has already shown its willingness to modify the framework when stakeholder feedback justified it. https://www.cms.gov/newsroom/fact-sheets/calendar-year-2024-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1782-f
2 · Reply
AxWiz
AxWiz Nov. 8 at 5:49 PM
$DVA If Warren is selling, perhaps we should too...
0 · Reply
Noname2022
Noname2022 Nov. 8 at 5:31 PM
$CRMD $DVA DaVita’s sequence: Reimbursement clarity → Real-world evidence → DaVita action.
0 · Reply
Noname2022
Noname2022 Nov. 8 at 9:05 AM
$CRMD $AKBA $DVA $FMS KCP asking for 3rd year of TDAPA & post tdapa reform consideration in 2027 to make permanent and billing for actual patient use (remove moral hazard) https://downloads.regulations.gov/CMS-2025-0240-0122/attachment_1.pdf
0 · Reply
Noname2022
Noname2022 Nov. 8 at 8:47 AM
$CRMD $AKBA $FMS $DVA ASN asking for 3rd year TDAPA extension https://www.asn-online.org/policy/webdocs/CY2026_ESRD_PPS_QIP_Final_Comment_Letter.pdf
2 · Reply
Noname2022
Noname2022 Nov. 6 at 5:31 PM
$DVA Defencath, available almost everywhere but NOT at Davita!
1 · Reply
BlizzardBear62
BlizzardBear62 Nov. 5 at 4:50 PM
$DVA cash-flow machine, defensive, adds near supports pay
0 · Reply
Noname2022
Noname2022 Nov. 4 at 11:01 PM
0 · Reply
Noname2022
Noname2022 Nov. 4 at 6:54 PM
$DVA Fresenius is already at 70% immunized on track for 85% for flu shots! Also they are using defencath to reduce CBRSIs by 70%! Davita operations having something to aspire too…
1 · Reply
Noname2022
Noname2022 Nov. 4 at 3:35 PM
1 · Reply
Noname2022
Noname2022 Nov. 4 at 10:02 AM
$DVA Fresenius has a competitive advantage on CBRSI’s
0 · Reply
Noname2022
Noname2022 Nov. 4 at 1:36 AM
$DVA DaVita (DVA) has spent $400–550 million per quarter on share repurchases in 2025 totaling well over a billion YTD while spending essentially nothing on implementing an FDA-approved, infection-reducing product (DefenCath) that directly targets catheter-related bloodstream infections (CRBSIs), one of the top two causes of death in their patient population.
0 · Reply